Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 11/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | PGC | P20142 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27210409 | 1.00 | TRHR (0.54) | TRHRACERENACE2CMA1 | |
| SCHEMBL30839651 | 0.92 | TRHR (0.53) | TRHRACERENACE2PGC | |
| SCHEMBL31649400 | 0.83 | DPP4 (0.53) | TRHRRENACE2PGCDPP4 | |
| SCHEMBL27705650 | 0.82 | ACE (0.46) | ACERENPGC | |
| SCHEMBL3692085 | 0.81 | ACE (0.77) | ACEACE2CMA1F2PRSS1 | |
| SCHEMBL22409423 | 0.81 | ACE (0.77) | ACEACE2CMA1F2PRSS1 | |
| SCHEMBL5900839 | 0.81 | ACE (0.77) | ACEACE2CMA1F2PRSS1 | |
| SCHEMBL3692081 | 0.81 | ACE (0.77) | ACEACE2CMA1F2PRSS1 | |
| SCHEMBL5900836 | 0.81 | ACE (0.77) | ACEACE2CMA1F2PRSS1 | |
| SCHEMBL8378100 | 0.81 | ACE (0.77) | ACEACE2CMA1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-05-02 | — | — | US | disclosed |
| WO-2024069524-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | NOVMETAPHARMA CO., LTD. (KR) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140955-A1 | PEG-MODIFIED CYCLIC DIPEPTIDES | LNPEP, ANPEP, DNPEP | TRHR 619/4885ACE 704/4885REN 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.